Prolocor Announces Results of NIH-funded Study Demonstrating That Platelet FcγRIIa Identifies Cancer Patients at Increased Risk of Death and Thrombotic Events
Excerpt from the Press Release:
PHILADELPHIA, PA / ACCESS Newswire / May 20, 2026 / Prolocor, Inc., a healthcare company developing the innovative diagnostic Prolocor pFCG™ test to identify patients at risk of thrombotic events, announced the publication of a recently completed study entitled Platelet FcγRIIa: A Novel Biomarker of Risk for Thromboembolism and Death in Cancer, in the Journal of Thrombosis and Thrombolysis.
The study supported by a grant from the NIH and completed by researchers at the University of Vermont Cancer Center suggests that platelet FcγRIIa may help identify cancer patients at greater risk of thromboembolic events and death. In a prospective study of 219 ambulatory patients beginning cancer-directed therapy, investigators found that higher expression of this platelet biomarker was associated with an increased risk of the combined outcome of arterial or venous thrombosis and death and was particularly linked to a greater risk of all-cause mortality. The findings point to platelet FcγRIIa as a promising biomarker that could improve risk assessment in oncology care.
View the full publication here: Platelet FcγRIIa: A Novel Biomarker of Risk for Thromboembolism and Death in Cancer.
“While additional studies are needed, these results indicate that platelet FcγRIIa could emerge as a valuable biomarker for identifying cancer patients who may face a greater risk of thrombosis and poor outcomes,” said Chris E. Holmes, MD, PhD, Department of Medicine, Division of Hematology and Oncology, University of Vermont Cancer Center.
Key Findings:
- Composite Outcomes: Patients with high pFCG had a significantly increased risk of arterial and venous thrombotic events (ATE/VTE) or death (Hazard Ratio [HR] 1.9; p=0.02).
- Mortality: High pFCG identified patients at greater risk of all-cause death (HR 2.5; p=0.009).
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?